BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

841 related articles for article (PubMed ID: 11175344)

  • 1. Identification of novel hypoxia dependent and independent target genes of the von Hippel-Lindau (VHL) tumour suppressor by mRNA differential expression profiling.
    Wykoff CC; Pugh CW; Maxwell PH; Harris AL; Ratcliffe PJ
    Oncogene; 2000 Dec; 19(54):6297-305. PubMed ID: 11175344
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function.
    Krieg M; Haas R; Brauch H; Acker T; Flamme I; Plate KH
    Oncogene; 2000 Nov; 19(48):5435-43. PubMed ID: 11114720
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of novel VHL target genes and relationship to hypoxic response pathways.
    Maina EN; Morris MR; Zatyka M; Raval RR; Banks RE; Richards FM; Johnson CM; Maher ER
    Oncogene; 2005 Jun; 24(28):4549-58. PubMed ID: 15824735
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.
    Zatyka M; da Silva NF; Clifford SC; Morris MR; Wiesener MS; Eckardt KU; Houlston RS; Richards FM; Latif F; Maher ER
    Cancer Res; 2002 Jul; 62(13):3803-11. PubMed ID: 12097293
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Constitutive activation of hypoxia-inducible genes related to overexpression of hypoxia-inducible factor-1alpha in clear cell renal carcinomas.
    Wiesener MS; Münchenhagen PM; Berger I; Morgan NV; Roigas J; Schwiertz A; Jürgensen JS; Gruber G; Maxwell PH; Löning SA; Frei U; Maher ER; Gröne HJ; Eckardt KU
    Cancer Res; 2001 Jul; 61(13):5215-22. PubMed ID: 11431362
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Loss of von Hippel-Lindau protein causes cell density dependent deregulation of CyclinD1 expression through hypoxia-inducible factor.
    Baba M; Hirai S; Yamada-Okabe H; Hamada K; Tabuchi H; Kobayashi K; Kondo K; Yoshida M; Yamashita A; Kishida T; Nakaigawa N; Nagashima Y; Kubota Y; Yao M; Ohno S
    Oncogene; 2003 May; 22(18):2728-38. PubMed ID: 12743597
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of ras and von Hippel-Lindau (VHL) gene mutations on hypoxia-inducible factor (HIF)-1alpha, HIF-2alpha, and vascular endothelial growth factor expression and their regulation by the phosphatidylinositol 3'-kinase/Akt signaling pathway.
    Blancher C; Moore JW; Robertson N; Harris AL
    Cancer Res; 2001 Oct; 61(19):7349-55. PubMed ID: 11585776
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Renal cell carcinoma- and pheochromocytoma-specific altered gene expression profiles in VHL mutant clones.
    Tsuchiya MI; Okuda H; Takaki Y; Baba M; Hirai S; Ohno S; Shuin T
    Oncol Rep; 2005 Jun; 13(6):1033-41. PubMed ID: 15870918
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of hypoxia-inducible factors in human renal cancer: relationship to angiogenesis and to the von Hippel-Lindau gene mutation.
    Turner KJ; Moore JW; Jones A; Taylor CF; Cuthbert-Heavens D; Han C; Leek RD; Gatter KC; Maxwell PH; Ratcliffe PJ; Cranston D; Harris AL
    Cancer Res; 2002 May; 62(10):2957-61. PubMed ID: 12019178
    [TBL] [Abstract][Full Text] [Related]  

  • 10. von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF.
    Hoffman MA; Ohh M; Yang H; Klco JM; Ivan M; Kaelin WG
    Hum Mol Genet; 2001 May; 10(10):1019-27. PubMed ID: 11331612
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis.
    Maxwell PH; Wiesener MS; Chang GW; Clifford SC; Vaux EC; Cockman ME; Wykoff CC; Pugh CW; Maher ER; Ratcliffe PJ
    Nature; 1999 May; 399(6733):271-5. PubMed ID: 10353251
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overproduction of vascular endothelial growth factor related to von Hippel-Lindau tumor suppressor gene mutations and hypoxia-inducible factor-1 alpha expression in renal cell carcinomas.
    Na X; Wu G; Ryan CK; Schoen SR; di'Santagnese PA; Messing EM
    J Urol; 2003 Aug; 170(2 Pt 1):588-92. PubMed ID: 12853836
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Contrasting effects on HIF-1alpha regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel-Lindau disease.
    Clifford SC; Cockman ME; Smallwood AC; Mole DR; Woodward ER; Maxwell PH; Ratcliffe PJ; Maher ER
    Hum Mol Genet; 2001 May; 10(10):1029-38. PubMed ID: 11331613
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vascular endothelial growth factor-B and vascular endothelial growth factor-C expression in renal cell carcinomas: regulation by the von Hippel-Lindau gene and hypoxia.
    Gunningham SP; Currie MJ; Han C; Turner K; Scott PA; Robinson BA; Harris AL; Fox SB
    Cancer Res; 2001 Apr; 61(7):3206-11. PubMed ID: 11306510
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The pVHL-associated SCF ubiquitin ligase complex: molecular genetic analysis of elongin B and C, Rbx1 and HIF-1alpha in renal cell carcinoma.
    Clifford SC; Astuti D; Hooper L; Maxwell PH; Ratcliffe PJ; Maher ER
    Oncogene; 2001 Aug; 20(36):5067-74. PubMed ID: 11526493
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulation of STRA13 by the von Hippel-Lindau tumor suppressor protein, hypoxia, and the UBC9/ubiquitin proteasome degradation pathway.
    Ivanova AV; Ivanov SV; Danilkovitch-Miagkova A; Lerman MI
    J Biol Chem; 2001 May; 276(18):15306-15. PubMed ID: 11278694
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of exon 2-encoded beta -domain of the von Hippel-Lindau tumor suppressor protein.
    Bonicalzi ME; Groulx I; de Paulsen N ; Lee S
    J Biol Chem; 2001 Jan; 276(2):1407-16. PubMed ID: 11024059
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transforming growth factor alpha is a target for the von Hippel-Lindau tumor suppressor.
    Knebelmann B; Ananth S; Cohen HT; Sukhatme VP
    Cancer Res; 1998 Jan; 58(2):226-31. PubMed ID: 9443397
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Specific oncolytic effect of a new hypoxia-inducible factor-dependent replicative adenovirus on von Hippel-Lindau-defective renal cell carcinomas.
    Cuevas Y; Hernández-Alcoceba R; Aragones J; Naranjo-Suárez S; Castellanos MC; Esteban MA; Martín-Puig S; Landazuri MO; del Peso L
    Cancer Res; 2003 Oct; 63(20):6877-84. PubMed ID: 14583486
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanism of regulation of the hypoxia-inducible factor-1 alpha by the von Hippel-Lindau tumor suppressor protein.
    Tanimoto K; Makino Y; Pereira T; Poellinger L
    EMBO J; 2000 Aug; 19(16):4298-309. PubMed ID: 10944113
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 43.